Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Net Income (2016 - 2025)

Historic Net Income for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.

  • China Pharma Holdings' Net Income rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3276.23%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
  • China Pharma Holdings' Net Income amounted to -$651482.0 in Q3 2025, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
  • China Pharma Holdings' Net Income's 5-year high stood at -$475976.0 during Q1 2023, with a 5-year trough of -$1.4 million in Q2 2024.
  • Moreover, its 5-year median value for Net Income was -$826669.0 (2021), whereas its average is -$902785.3.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 641855.51% in 2021, then skyrocketed by 6326.01% in 2025.
  • China Pharma Holdings' Net Income (Quarter) stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then soared by 46.79% to -$651482.0 in 2025.
  • Its last three reported values are -$651482.0 in Q3 2025, -$528367.0 for Q2 2025, and -$785572.0 during Q1 2025.